IGI Logo

Sun Pharmaceuticals Industrial limited reported total revenue from operations at ₹8431.3 crores up by 4.3% YoY from ₹8078 crores in Q4FY20. Domestic business has done well for the company up by 12.9% at ₹2671 Crores while USA business down by 1% ₹2694 Crores. Profit before tax for the quarter at ₹1575 crores up by 88% as compared to ₹838 crores in Q4FY20. Profit after tax for the quarter at ₹848 crores in Q4FY21 as compared to ₹494 crores up by 71% in Q4FY20. Company reported an exceptional loss of ₹551.6 crores with regards to taro pharmaceuticals multi-year investigations in Q4FY21. Company reported EPS of ₹3.7 for Q4FY21 and 12.1 For FY2021.

Sunpharma reported numbers in line with market expectation, Top line growth was muted while bottom line has done very well this quarter as the company has improved its EBITDA margins. Company has also reported a one time exceptional item, loss of ₹551 crores for the Taro Pharmaceuticals investigation settlement, Taro Pharmaceuticals is subsidiary company of Sun pharmaceuticals. 

Above views are of the author and not of the website kindly read disclaimer